



BAFNA PHARMACEUTICALS LTD.,

REGD. OFFICE: "BAFNA TOWERS" 299, THAMBU CHETTY STREET, CHENNAI-600 001, INDIA.
PHONE:+044-25267517/25270992/42677555, FAX:91-44-25231264, mail: info@bafnapharma.com, website: www.bafnapharma.com
CIN: L24294TN1995PLC030698

August 8, 2017

Listing Department
The Bombay Stock Exchange Limited
P J Towers
Dalal Street
Mumbai – 400 001

Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E)
Mumbai – 400051

SCRIP CODE: 532989
SCRIP SYMBOL: BAFNAPHARM
ISIN: INE878I01014

Dear Sir,

Sub: Unaudited Financial Statements and Limited Review Report for the quarter
ended 30th June, 2017

Ref: Regulation 30 & 33 of SEBI (LODR) Regulations, 2015

Unaudited Financial Statements and Limited Review Report for the quarter ended 30th
June, 2017 under regulation 30 & 33 of SEBI (LODR) Regulations, 2015, is hereby
enclosed for your reference.

Request you to take the same on record.

Thanking you.

Yours faithfully,
For BAFNA PHARMACEUTICALS LIMITED

Mahaveer Chand Bafna
Managing Director
(DIN: 01458211)

Limited Review Report for the Quarter Ending 30.06.2017

To
The Board of Directors
M/s Bafna Pharmaceuticals Ltd
No 299 Thambu Chetty Street
Chennai - 600001

We have reviewed the accompanying statement of unaudited financial results of M/S Bafna Pharmaceuticals Limited ("the Company") for the period ended 30.06.2017 (the "statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Chennai
Date : 30.06.2017

For ABHAY JAIN & Co.,
Chartered Accountants
FRN : 000008S


(A.K. JAIN)
Partner
M No.70224



BAFNA PHARMACEUTICALS LIMITED (CIN L24294TN1995PLC030698)

Regd office: Old No: 299, New No: 68, THAMBU CHETTY STREET, CHENNAI- 600 001

Unaudited Standalone Financial Results for the Quarter Ended 30 th June 2017

PART I		(Rs. In Lakhs)				
Sl.No	Particulars	3 months ended (30-06-2016)	Preceeding 3 months ended (31-03-2017)	Corresponding 3 months ended (30.06.2016)	For the Current Year ended (30.06.2017)	For the Previous Year ended (31.03.2017)
		Unaudited	Audited	Unaudited	Unaudited	Audited
I	Revenue From operations	910.38	1,143.82	2,115.75	910.38	6,496.15
II	Other Income	7.23	(0.93)	20.00	7.23	114.02
III	Total Income (I+II)	917.61	1,142.89	2,135.75	917.61	6,610.17
IV	EXPENSES					
a)	Cost of materials consumed	601.54	671.09	433.56	601.54	2,030.62
b)	Purchases of Stock-in-Trade	-	724.26	1,340.50	-	4,020.06
c)	Changes in inventories of finished goods, Stock-in -Trade and work-in-progress	393.60	(213.77)	19.48	393.60	(309.16)
d)	Employee benefits expense	158.38	188.93	155.71	158.38	662.26
e)	Finance costs	197.49	214.52	291.37	197.49	1,133.68
f)	Depreciation and amortization expenses	92.79	84.58	101.43	92.79	389.13
g)	Other expenses	64.81	378.35	88.96	64.81	614.12
	Total expenses (IV)	1,508.61	2,047.96	2,431.01	1,508.61	8,540.71
V	Profit/(loss) before exceptional items and tax (I-IV)	(591.00)	(905.07)	(295.26)	(591.00)	(1,930.54)
VI	Exceptional Items					
VII	Profit/ (loss) before exceptions items and tax(V-VI)	(591.00)	(905.07)	(295.26)	(591.00)	(1,930.54)
	Tax expense:					
VIII	(1) Current tax	-	-	-	-	-
	(2) Deferred tax	169.66	(67.83)	(5.21)	169.66	(83.52)
IX	Profit (Loss) for the period from continuing operations (VII-	(760.66)	(837.25)	(290.05)	(760.66)	(1,847.02)
X	Profit/(loss) from discontinued operations	-	-	-	-	-
XI	Tax expenses of discontinued operations	-	-	-	-	-
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	(760.66)	(837.25)	(290.05)	(760.66)	(1,847.02)
	Other Comprehensive Income					
XIV	A. (i) Items that will not be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-
	B. (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to	-	-	-	-	-
XV	Total Comprehensive Income for the period (XIII+XIV)Comprising Profit (Loss) and Other.comprehensive Income for the period)	(760.66)	(837.25)	(290.05)	(760.66)	(1,847.02)
	Earnings per equity share (for continuing operation):					
XVI	(1) Basic	(4.08)	(4.49)	(1.55)	(4.08)	(9.90)
	(2) Diluted	(4.08)	(4.49)	(1.55)	(4.08)	(9.90)
XVII	Earnings per equity share (for discontinued operation):					
	(1) Basic	-	-	-	-	-
	(2) Diluted	-	-	-	-	-
XVIII	Earning per equity share (for discontinued & continuing operation)					
	(1)Basic	(4.08)	(4.49)	(1.55)	(4.08)	(9.90)
	(2) Diluted	(4.08)	(4.49)	(1.55)	(4.08)	(9.90)



1. The above unaudited quarterly financial results were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at their Meeting held on 08.08.2017

2. Status of Investor Complaints.:

I	Opening balance	NIL
II	Pending at the beginning of the quarter	NIL
III	No. of complaints received and disposed off during the quarter	NIL
IV	Complaints pending at the end of the quarter	NIL

3. The Company operates only in one segment, ie. Pharmaceutical formulations, as such reporting is done on a single segment basis.

4. The Limited Review as required under Clause 41 of the Listing Agreement has been completed by the statutory Auditors for the Quarter ended 30.06.2017

5. The MD and CFO certificate in respect of the above results in terms of the requirement of Clause 41 of the Listing Agreement has been placed before the Board of Directors.

Place: Chennai

Date: 08.08.2017

For BAFNA PHARMACEUTICALS LIMITED



A handwritten signature in blue ink, appearing to read 'Bafna Mahaveer Chand', written over the printed name.

(BAFNA MAHAVEER CHAND)
MANAGING DIRECTOR